Novartis Ag Adr (NVS)

Oct 29, 2026

Novartis AG (NVS) Seasonal returns chart - Yahoo Finance UK

Oct 29, 2026

Oct 29, 2026

Novartis AG (NVS) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 79/100 - GuruFocus

Oct 29, 2026

Oct 29, 2026

China Upends Global Drug Development With Cheap and Rapid Human Trials - Bloomberg.com

Oct 29, 2026

Oct 29, 2026

INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised - Zacks Investment Research

Oct 29, 2026

Oct 29, 2026

Should You Buy Royalty Pharma Stock Before Nov. 4? - The Motley Fool

Oct 29, 2026

Oct 29, 2026

Novartis AG (NVS) Stock Forecasts - Yahoo! Finance Canada

Oct 29, 2026

Oct 29, 2026

Novartis AG : Bernstein reiterates its Neutral rating - www.marketscreener.com

Oct 29, 2026

Oct 29, 2026

Novartis AG : JP Morgan reiterates its Buy rating - marketscreener.com

Oct 29, 2026

Oct 29, 2026

Novartis AG Stock 12‑Month Price Target Raised to $158.2, Implies 1% Upside - TradingView

Oct 29, 2026

Oct 28, 2026

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.

Oct 28, 2026

Oct 28, 2026

How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3? - Zacks Investment Research

Oct 28, 2026

Oct 28, 2026

The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie - Zacks Investment Research

Oct 28, 2026

Oct 27, 2026

Novartis AG (NVS) Stock Forecasts - Yahoo Finance

Oct 27, 2026

Oct 27, 2026

What Novartis (NVS) Said on Its Q3 Earnings Call - Yahoo Finance

Oct 27, 2026

Oct 27, 2026

Novartis AG (NVS) (Q3 2026) Earnings Call Highlights: Raised Gui - GuruFocus

Oct 27, 2026

Oct 27, 2026

Novartis AG (NVS) (Q3 2026) Earnings Call Highlights: Raised Guidance and Priority Brand ... - Yahoo Finance

Oct 27, 2026

Oct 27, 2026

Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9B Avidity HitNovartis (NYSE:NVS) - Benzinga

Oct 27, 2026

Oct 27, 2026

4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential - Zacks Investment Research

Oct 27, 2026

Oct 27, 2026

NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss - Zacks Investment Research

Oct 27, 2026

Oct 27, 2026

Novartis takes $1.9bn writedown on key drug after blockbuster Avidity acquisition - Financial Times

Oct 27, 2026

Oct 27, 2026

NOVARTIS AG N (NOTA.DU) Q3 FY2026 earnings call transcript - Yahoo Finance

Oct 27, 2026

Oct 27, 2026

The Zacks Analyst Blog Highlights Intel, Novartis AG, Itau Unibanco and AMREP - Yahoo Finance

Oct 27, 2026

Oct 27, 2026

Novartis Raises Outlook on Growth of New Medicines - Bloomberg.com

Oct 27, 2026

Oct 27, 2026

Novartis lifts profit outlook as new medicines counter generic erosion (NVS:NYSE) - Seeking Alpha

Oct 27, 2026

Oct 27, 2026

Novartis reports Q3 core EPS $2.46 vs. $2.25 last year - TipRanks

Oct 27, 2026

Oct 27, 2026

Novartis AG reports results for the quarter ended September 30Earnings Summary - TradingView

Oct 27, 2026

Oct 27, 2026

Novartis Q3 Core Earnings, Net Sales Increase; 2026 Net Sales Growth Outlook Maintained - Yahoo Finance

Oct 27, 2026

Oct 27, 2026

Novartis: Q3 Earnings Snapshot - Yahoo Finance

Oct 27, 2026

Oct 26, 2026

Top Analyst Reports for Intel, Novartis & Itau Unibanco - Zacks Investment Research

Oct 26, 2026

Oct 26, 2026

Earnings To Watch: Novartis AG (XSWX:NOVN) Q3 2026 -- GF Value Sees 8% Downside - Yahoo Finance

Oct 26, 2026

Oct 26, 2026

Novartis AG : UBS sticks Neutral - marketscreener.com

Oct 26, 2026

Oct 26, 2026

Novartis MS Pill Trials Trigger Analyst Skepticism on Peak Sales - Bloomberg.com

Oct 26, 2026

Oct 26, 2026

Novartis AG : Gets a Neutral rating from RBC - marketscreener.com

Oct 26, 2026

Oct 26, 2026

Novartis AG : Gets a Neutral rating from Barclays - marketscreener.com

Oct 26, 2026

Oct 25, 2026

Novartis: Strong Drug Growth Faces A Tougher Test As Patent Losses And Pipeline Setbacks Mount - Seeking Alpha

Oct 25, 2026

Oct 25, 2026

Novartis Reports Positive Results from Late-stage Studies for Remibrutinib - marketscreener.com

Oct 25, 2026

Oct 23, 2026

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity - Yahoo Finance

Oct 23, 2026

Oct 23, 2026

Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple SclerosisSlideshow - Seeking Alpha

Oct 23, 2026

Oct 23, 2026

Novartis AG Remibrutinib in MS Investor Call Transcript - GuruFocus

Oct 23, 2026

Oct 23, 2026

Novartis AG (NVS) Stock Down 3.3% but Still Overvalued -- GF Score: 75/100 - GuruFocus

Oct 23, 2026

Oct 23, 2026

Novartis AG : RBC is Neutral - marketscreener.com

Oct 23, 2026

Oct 23, 2026

Novartis Multiple Sclerosis Pill Missed Expectations in Key Study - Bloomberg.com

Oct 23, 2026

Oct 23, 2026

Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib - Reuters

Oct 23, 2026

Oct 23, 2026

Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study - Bloomberg.com

Oct 23, 2026

Oct 23, 2026

Novartis AG Stock (NVS) Moved Down by 3.61% on Oct 23: Facts Behind the Movement - TradingKey

Oct 23, 2026

Oct 23, 2026

Novartis AG Estimates – BX:NOT - TradingView

Oct 23, 2026

Oct 23, 2026

Novartis AG expected to post earnings of $2.29 a shareEarnings Preview - TradingView

Oct 23, 2026

Oct 22, 2026

AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy - Zacks Investment Research

Oct 22, 2026

Oct 22, 2026

Novartis AG Lobbying Profile, 2004 - OpenSecrets

Oct 22, 2026

Oct 21, 2026

Earnings Preview: Novartis AG to Report Financial Results on October 27 - Moomoo

Oct 21, 2026